Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety study of camrelizumab in solid tumor patients
ChiCTR2100043527Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Nonhematologic neoplasms, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Progression-free survival. Started Mar 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100043527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043527.